Member Directory

Amplia Therapeutics

Website: https://www.ampliatx.com/site/content/

Member Contact: Dr John Lambert

Position: CEO and Managing Director

Industry: Biotech & Pharmaceuticals

Company Profile:

Amplia Therapeutics Limited (ASX: ATX) is an Australian, publicly-listed, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.

Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and medicinal chemistry researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation.

Home

News & opinion

Member Directory

Events